Autophagic effect of SAM-competitive EZH2 inhibitors on cancer cells

  title={Autophagic effect of SAM-competitive EZH2 inhibitors on cancer cells},
  author={Tsang-Pai Liu and Pei-Ming Yang},
  journal={Cancer cell \& microenvironment},
Enhancer of zeste homolog 2 (EZH2) is an epigenetic enzyme that mediates gene silencing through tri-methylation of histone H3 lysine 27 (H3K27-me3). Because overexpression of EZH2 in tumors is frequently found, its inhibition has been viewed as a novel anticancer strategy. Numerous small-molecule EZH2 inhibitors have been developed in recent years. S-adenosyl- L -homocysteine (SAH) hydrolase inhibitor, such as 3-Deazaneplanocin A (DZNep), and S-adenosyl-L-methionine (SAM)-competitive inhibitor… Expand

Figures from this paper

Investigation of EZH2 pathways for novel epigenetic treatment strategies in oropharyngeal cancer
Inhibition of EZH2 has anti-tumorigenic effects on OPSCC cells in culture that is more pronounced in HPV-positive cell lines, a promising epigenetic target for the treatment of OPSCC. Expand
Epigenetics of oropharyngeal squamous cell carcinoma: opportunities for novel chemotherapeutic targets
Important epigenetic pathways in human papillomavirus (HPV) positive and negative OPSCC are summarized, as well as the potential clinical utility of this knowledge are summarized. Expand


S-Adenosyl-l-methionine-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cells
It is found that GSK343 but not DZNep induced autophagic cell death of cancer cells, and for the first time, it is shown that it acts as an autophagy inducer. Expand
Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation
  • W. Qi, H. Chan, +25 authors E. Li
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences
  • 2012
A potent and selective small molecule inhibitor, EI1, is developed, which inhibits the enzymatic activity of Ezh2 through direct binding to the enzyme and competing with the methyl group donor S-Adenosyl methionine, providing strong validation of EzH2 as a potential therapeutic target for the treatment of cancer. Expand
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
GSK126, a potent, highly selective, S-adenosyl-methionine-competitive, small-molecule inhibitor of EZH2 methyltransferase activity, decreases global H3K27me3 levels and reactivates silenced PRC2 target genes and markedly inhibits the growth of EzH2 mutant DLBCL xenografts in mice are demonstrated. Expand
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.
The discovery of EPZ005687 is reported, a potent inhibitor of EZH2 that reduces H3K27 methylation in various lymphoma cells; this translates into apoptotic cell killing in heterozygous Tyr641 or Ala677 mutant cells, with minimal effects on the proliferation of wild-type cells. Expand
Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma
The results show that the combination of autophagy inducers with SAHA might be attractive for the treatment of HCC and pharmacological targeting of Autophagy provides promise for the management of cancer therapy. Expand
Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells.
The results demonstrate the unique feature of DZNep as a novel chromatin remodeling compound and suggest that pharmacologic reversal of PRC2-mediated gene repression by DzNep may constitute a novel approach for cancer therapy. Expand
An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1.
UNC1999 was the first orally bioavailable inhibitor that has high in vitro potency for wild-type and mutant EZH2 as well as EzH1, a closely related H3K27 methyltransferase that shares 96% sequence identity with EZh2 in their respective catalytic domains. Expand
Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2.
This work has identified highly potent, selective, SAM-competitive, and cell-active EZH2 inhibitors, including GSK926 and GSK343, which are small molecule chemical tools that would be useful to further explore the biology of EZh2. Expand
Methotrexate induces apoptosis through p53/p21-dependent pathway and increases E-cadherin expression through downregulation of HDAC/EZH2.
The anticancer mechanism of MTX acts through initiation of p53-dependent apoptosis and restoration of E-cadherin expression by downregulation of HDAC/EZH2. Expand
EZH2: biology, disease, and structure-based drug discovery
This review addresses the current understanding of the oncogenic role of EZH2, including its PRC2-dependent transcriptional repression and PRC 2-independent gene activation, and comprehensively addresses the architecture of thePRC2 complex and the crucial roles of each subunit. Expand